Blood involvement by mycosis fungoides (MF)/Sézary syndrome (SS) influences prognosis and therapeutic decisions. MF/SS blood stage is currently determined by absolute CD4 + CD26− or CD4 + CD7‐cell counts, which quantification method may overestimate MF/SS by including CD26− or CD7− normal CD4+ T‐cells, or underestimate disease burden when MF/SS cells show incomplete loss of CD26 and/or CD7. Recently, through the standardization effort led by the International Clinical Cytometry Society (ICCS), recommendation was made to quantify MF/SS by enumerating immunophenotypically aberrant CD4+ T‐cells, rather than CD26− or CD7− in isolation.

中文翻译：

---

与 CD26- 或 CD7- CD4+ T 细胞的定量相比，免疫表型异常的测定可以更好地评估蕈样肉芽肿/Sézary 综合征的外周血受累情况

蕈样肉芽肿 (MF)/Sézary 综合征 (SS) 的血液受累影响预后和治疗决策。MF/SS 血液分期目前由绝对 CD4 + CD26- 或 CD4 + CD7 细胞计数确定，这种量化方法可能会通过包含 CD26- 或 CD7- 正常 CD4+ T 细胞来高估 MF/SS，或者当 MF/ SS 细胞显示 CD26 和/或 CD7 的不完全丧失。最近，通过国际临床细胞计数协会 (ICCS) 领导的标准化工作，建议通过计数免疫表型异常的 CD4+ T 细胞而不是孤立的 CD26- 或 CD7- 来量化 MF/SS。